Hans Lilja

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
    Amine Benchikh
    Hopital Bichat Claude Bernard, Paris, France
    BMC Cancer 10:635. 2010
  2. ncbi Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50
    Hans Lilja
    Department of Clinical Laboratories, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:1210-9. 2011
  3. ncbi Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
    Hans Lilja
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center New York, New York 10065, USA
    Nat Rev Cancer 8:268-78. 2008
  4. ncbi Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years
    Hans Lilja
    Department of Laboratory Medicine, Lund University, University Hospital UMAS, Malmo, Sweden
    J Clin Oncol 25:431-6. 2007
  5. ncbi Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy
    Matthew Frank O'Brien
    Departmen of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:3591-7. 2009
  6. ncbi Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 307 E 63rd St, New York, NY 10021, USA
    Eur Urol 56:753-60. 2009
  7. ncbi Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy
    Sven Wenske
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 124:659-63. 2009
  8. ncbi Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer
    Robert J Klein
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Prev Res (Phila) 3:611-9. 2010
  9. ncbi Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study
    David Ulmert
    Departments of Laboratory Medicine and Clinical Sciences in Malmö, Lund University, University Hospital UMAS, Malmo, Sweden
    BMC Med 6:6. 2008
  10. ncbi A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 16:3232-9. 2010

Collaborators

Detail Information

Publications109 found, 100 shown here

  1. ncbi A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France
    Amine Benchikh
    Hopital Bichat Claude Bernard, Paris, France
    BMC Cancer 10:635. 2010
    ..Here we investigate the properties of our panel in men subject to clinical work-up before biopsy...
  2. ncbi Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50
    Hans Lilja
    Department of Clinical Laboratories, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:1210-9. 2011
    ..This provides replication using an independent data set and allows estimates of the association between early PSA and subsequent advanced cancer (clinical stage ≥T3 or metastases at diagnosis)...
  3. ncbi Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
    Hans Lilja
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center New York, New York 10065, USA
    Nat Rev Cancer 8:268-78. 2008
    ..Much current research is directed at establishing the most appropriate uses of PSA testing and at developing methods to improve on the conventional PSA test...
  4. ncbi Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years
    Hans Lilja
    Department of Laboratory Medicine, Lund University, University Hospital UMAS, Malmo, Sweden
    J Clin Oncol 25:431-6. 2007
    ..We examined whether prostate-specific antigen (PSA) forms and human kallikrein 2 (hK2) measured at age 44 to 50 years predict long-term risk of incident prostate cancer...
  5. ncbi Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy
    Matthew Frank O'Brien
    Departmen of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:3591-7. 2009
    ..We assessed whether pretreatment PSA velocity (PSAV) or doubling time (PSADT) predicted outcome in men undergoing radical prostatectomy and whether any definition enhanced accuracy of an outcome prediction model...
  6. ncbi Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 307 E 63rd St, New York, NY 10021, USA
    Eur Urol 56:753-60. 2009
    ..It has been suggested that changes in prostate-specific antigen (PSA) over time (ie, PSA velocity [PSAV]) aid prostate cancer detection. Some guidelines do incorporate PSAV cut points as an indication for biopsy...
  7. ncbi Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy
    Sven Wenske
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 124:659-63. 2009
    ..720 to 0.726, p=0.2). fPSA is routinely measured during prostate cancer detection. We suggest that the role of fPSA in aiding preoperative prediction should be investigated in further cohorts...
  8. ncbi Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer
    Robert J Klein
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Prev Res (Phila) 3:611-9. 2010
    ..874 versus 0.866), providing proof in principle to clinical application for our findings...
  9. ncbi Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study
    David Ulmert
    Departments of Laboratory Medicine and Clinical Sciences in Malmö, Lund University, University Hospital UMAS, Malmo, Sweden
    BMC Med 6:6. 2008
    ..We aimed to determine whether this association holds for advanced cancers, defined as clinical stage T3 or higher, or skeletal metastasis at the time of the cancer diagnosis...
  10. ncbi A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 16:3232-9. 2010
    ..Although this model accurately predicts the result of biopsy in unscreened men, its properties for men with a history of PSA screening have not been fully characterized...
  11. ncbi Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BMJ 341:c4521. 2010
    ....
  12. ncbi Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 116:2612-20. 2010
    ..However, the association between PSA and cancer probably depends on a man's recent screening history...
  13. ncbi Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened popula
    David Ulmert
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:835-41. 2008
    ..We tested whether total prostate-specific antigen velocity (tPSAv) improves accuracy of a model using PSA level to predict long-term risk of prostate cancer diagnosis...
  14. ncbi TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
    Daniel C Danila
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 60:897-904. 2011
    ..AA treatment results in dramatic declines in prostate-specific antigen (PSA) in some patients and no declines in others, suggesting the presence of molecular determinants of sensitivity in tumors...
  15. ncbi A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 20:255-61. 2011
    ..The clinical significance of biopsy-detectable cancers in men classified as low-risk by this panel remains unclear...
  16. ncbi The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy
    Andrew J Vickers
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 121:2212-7. 2007
    ..Strategies for prostate cancer screening should be based on thorough understanding of the interaction of kallikrein-related biomarkers with prostate pathobiology...
  17. ncbi Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy
    Anders S Bjartell
    Departments of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4130-8. 2007
    ..We investigated whether these markers are related to biochemical recurrence and whether addition of the markers improves prediction of recurring disease...
  18. ncbi Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels
    Xing Xu
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 19:2035-42. 2010
    ..Therefore, we wished to determine the association between SNPs at MSMB, the gene encoding beta-MSP, and the levels of prostate-produced biomarkers beta-MSP, PSA, and human kallikrein 2 (hK2) in blood and semen...
  19. ncbi Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry
    Akos Vegvari
    Clinical Protein Science and Imaging, Dept of Measurement Technology and Industrial Electrical Engineering, Lund University, Lund, Sweden
    Clin Biochem 45:331-8. 2012
    ..In order to enable the development of new PSA assays and progress the understanding of the biology of PSA we have analyzed PSA in seminal plasma...
  20. ncbi Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:907-12. 2010
    ..We determined whether prostate specific antigen velocity could predict repeat biopsy results in men with persistently increased prostate specific antigen after initial negative biopsy...
  21. ncbi Susceptibility loci associated with prostate cancer progression and mortality
    David J Gallagher
    Department of Medicine, Clinical Genetics Service, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, Albert Einstein College of Medicine, New York, New York 10065, USA
    Clin Cancer Res 16:2819-32. 2010
    ..Prostate cancer is a heterogeneous disease with a variable natural history that is not accurately predicted by currently used prognostic tools...
  22. ncbi Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
    Thomas Steuber
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 118:1234-40. 2006
    ..Measurements of fPSA and hK2 improve on our ability to counsel patients prior to treatment as to their risk of BCR...
  23. ncbi Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer
    Thomas Steuber
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Chem 53:233-40. 2007
    ..We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) and prostate-specific antigen (PSA) with prostate cancers of unfavorable prognosis...
  24. ncbi Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men
    Robert J Klein
    Program in Cancer Biology and Genetics, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 61:471-7. 2012
    ..Although case-control studies have identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer, the clinical role of these SNPs remains unclear...
  25. ncbi Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival
    Pauliina Helo
    Departments of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Chem 55:765-73. 2009
    ..e., prostate-specific antigen (PSA)] and KLK2 mRNAs. We also assessed the association of CTCs with disease characteristics and survival...
  26. ncbi Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C
    David Ulmert
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital UMAS, Malmo, Sweden
    Clin Chem 52:235-9. 2006
    ..We compared the effects of long-term storage on fPSA, total PSA (tPSA), and complexed PSA (cPSA) in serum vs EDTA-plasma samples...
  27. ncbi Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy
    Thomas Steuber
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 120:1499-504. 2007
    ..0.715, p=0.039). In this setting, hK2 did not add diagnostic information. Measurements of individual forms of suPAR and PSA isoforms contributed significantly to discrimination of men with PCa from those with no evidence of malignancy...
  28. ncbi A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, East 63rd Street, New York, NY 10021, USA
    BMC Med 6:19. 2008
    ..We set out to determine whether a multivariable model including four kallikrein forms (total, free, and intact PSA, and human kallikrein 2 (hK2)) could predict prostate biopsy outcome in previously unscreened men with elevated total PSA...
  29. ncbi Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues
    Yue Cao
    Department of Urology, University Hospital Malmo, Lund University, Lund, Sweden
    Prostate 57:196-204. 2003
    ..Previous studies have localized PCI in the male genital tract. Here we have performed a detailed investigation of PCI expression in the prostatic tissues, metastases, and cell lines...
  30. ncbi Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer
    Anders Christensson
    Division of Nephrology, Department of Clinical Sciences, Lund University, University Hospital, Malmo, Sweden
    BJU Int 107:1769-74. 2011
    ..Diagnostic (exploratory cohort)...
  31. ncbi Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males
    Camilla Valtonen-Andre
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    J Androl 29:330-7. 2008
    ..This suggests that MSP in serum can be used as a marker of prostate secretion, despite the contribution from extra prostatic tissues...
  32. ncbi Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics
    Andreas Lenshof
    Department of Electrical Measurements, Lund University, Box 118, 221 00 Lund, Sweden
    Anal Chem 81:6030-7. 2009
    ..PSA was detected by good linearity (R(2) > 0.99) in the generated plasma via fluorescence readout without any signal amplification at clinically relevant levels (0.19-21.8 ng/mL)...
  33. ncbi A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index
    David Ulmert
    Department of Laboratory Medicine, Lund University, Skane University Hospital, Malmo, Sweden
    Eur Urol 62:78-84. 2012
    ..The Bone Scan Index (BSI) is predictive of survival in patients with progressive prostate cancer (PCa), but the popularity of this metric is hampered by the tedium of the manual calculation...
  34. ncbi Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples
    Akos Vegvari
    Clinical Protein Science and Imaging, Dept of Measurement Technology and Industrial Electrical Engineering, Lund University, BMC C13, SE 221 84 Lund, Sweden
    J Proteomics 75:202-10. 2011
    ..We could unambiguously identify PSA in clinical samples by all detectable tryptic peptides, which were found to be common in several isoforms...
  35. ncbi Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication
    Andrew Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:2493-8. 2010
    ..We aimed to replicate our findings in a large, independent, representative, population-based cohort...
  36. ncbi Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening
    Caroline J Savage
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, New York, NY 10065, USA
    Cancer Epidemiol Biomarkers Prev 19:1201-7. 2010
    ..We sought to describe empirically the distribution of lead times between an elevated prostate-specific antigen (PSA) and subsequent prostate cancer diagnosis...
  37. ncbi Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition
    Andrew J Stephenson
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:3973-8. 2006
    ..Ten definitions of BCR were evaluated to identify the one that best explains metastatic progression...
  38. ncbi Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden
    Laila Bruun
    Department of Nephrology and Transplantation, Lund University, University Hospital UMAS, Malmo, Sweden
    Prostate 65:216-21. 2005
    ..This study aimed to determine the long-term intra-individual variation for PSA in healthy men...
  39. ncbi Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland
    Anders Bjartell
    Department of Urology, Malmo University Hospital, Lund University, Malmo, Sweden
    Prostate 66:591-603. 2006
    ..The current aims were to investigate diagnostic use of tissue expression and immunodetection in serum of CRISP-3 for detection or monitoring of PCa...
  40. ncbi A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue
    Camilla Valtonen-Andre
    Lund University, Division of Clinical Chemistry, Department of Laboratory Medicine, University Hospital MAS, S 205 02 Malmo, Sweden
    Biol Chem 388:289-95. 2007
    ..Studies on human prostate cancer specimens showed immunohistochemical staining of both tumor and benign glandular cells. Our results suggest that PSMP is an important protein with significance in prostate cancer...
  41. ncbi ENSAM: Europium Nanoparticles for Signal enhancement of Antibody Microarrays on nanoporous silicon
    Kerstin Jaras
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Lund, Sweden
    J Proteome Res 7:1308-14. 2008
    ..In addition, proof of principle was shown for analyzing PSA in plasma obtained from patients undergoing clinical PSA-testing...
  42. ncbi Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation
    Laila Bruun
    Department of Nephrology and Transplantation, Lund University, University Hospital, Malmo, Sweden
    J Urol 171:1432-5. 2004
    ..We studied glomerular filtration dependent elimination of fPSA and hK2 in patients with renal insufficiency undergoing successful renal transplantation...
  43. ncbi Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues
    A Yvonne Olsson
    Department of Laboratory Medicine, Lund University, University Hospital UMAS, S 205 02 Malmo, Sweden
    Int J Cancer 113:290-7. 2005
    ..Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html...
  44. ncbi Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms
    Akos Vegvari
    Div Clinical Protein Science and Imaging, Dept of Measurement Technology and Industrial Electrical Engineering, Lund University, BMC C13, SE 221 84 Lund, Sweden
    J Proteomics 73:1137-47. 2010
    ..The high accuracy annotations were obtained by fast turnaround MALDI-Orbitrap analysis from excised and digested gel bands. Multiple PSA forms were identified utilizing a combination of MASCOT and SEQUEST search engines...
  45. ncbi miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions
    Zandra Hagman
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Malmo, Sweden
    Int J Cancer 127:2768-76. 2010
    ..Our findings provide new insight into the role of miR-34c in the prostate, exhibiting tumor suppressing effects on proliferation, apoptosis and invasiveness...
  46. ncbi Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer
    Margaret A Leversha
    Molecular Cytogenetics Core Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 15:2091-7. 2009
    ....
  47. ncbi The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 16:4374-81. 2010
    ..We hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study...
  48. ncbi Prostate kallikrein markers in diagnosis, risk stratification and prognosis
    David Ulmert
    Department of Urology, University Hospital Malmo, Lund University, Sweden
    Nat Rev Urol 6:384-91. 2009
    ..We review current and past reports on the prostate kallikreins PSA and hK2 in relation to pathology and epidemiology...
  49. ncbi Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age
    Charlotta Sävblom
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Malmo University Hospital, Malmo, Sweden
    Prostate 65:66-72. 2005
    ..We also compared age-related changes of PSA-forms in blood from young versus older men...
  50. ncbi Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer
    Daniel C Danila
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:7053-8. 2007
    ..We evaluated the association of baseline circulating tumor cell (CTC) number with clinical characteristics and survival in patients with castrate metastatic disease considered for different hormonal and cytotoxic therapies...
  51. ncbi Screening for prostate cancer: early detection or overdetection?
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Annu Rev Med 63:161-70. 2012
    ..In current U.S. practice, however, many men who are screened are unlikely to benefit, most men found to have low-risk cancers are referred for unnecessary curative treatment, and much treatment is given at low-volume centers...
  52. ncbi Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 27:398-403. 2009
    ..We aimed to assess the published evidence for the clinical utility of PSA dynamics in this population...
  53. ncbi An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 103:462-9. 2011
    ....
  54. ncbi Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively
    M Frank O'Brien
    Department of Surgery Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 128:2373-81. 2011
    ..Although evidence that certain PSAV definitions help to predict PCSM in the cohort exist, the value of incorporating PSAV in predictive models to assist in determining eligibility for conservative management is, at best, uncertain...
  55. ncbi Androgen receptor CAG repeat length correlates with semen PSA levels in adolescence
    Yvonne Lundberg Giwercman
    Department of Urology, Malmo University Hospital, Lund University, Malmo, Sweden
    Prostate 59:227-33. 2004
    ..Our aim was to investigate whether CAG repeat number might have an impact on prostate function in adolescence...
  56. ncbi Tumor markers in prostate cancer I: blood-based markers
    Shahrokh F Shariat
    Department of Urology and Division of Medical Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA
    Acta Oncol 50:61-75. 2011
    ....
  57. ncbi The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin
    A Yvonne Olsson
    Wallenberg Laboratories Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, Entr 46, 4th fl University Hospital UMAS, S 205 02 Malmo, Sweden
    Gene 343:347-55. 2004
    ..KLK15 appeared to be functional, thus, we predict that it generates a protease with specificity similar to that of the human ortholog...
  58. ncbi Testosterone as a predictor of pathological stage in clinically localized prostate cancer
    Ginger Isom-Batz
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 173:1935-7. 2005
    ..4). CONCLUSIONS: On multivariate analysis low preoperative total testosterone was associated with advanced pathological stage but not with BCR. Future studies are warranted with data on more patients who have progressed...
  59. ncbi Systematic review of statistical methods used in molecular marker studies in cancer
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Cancer 112:1862-8. 2008
    ..In the current study, the experimental designs and statistical methods used in contemporary molecular marker studies are reviewed, particularly with respect to whether these evaluated a marker's clinical value...
  60. ncbi Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen
    A Yvonne Olsson
    Wallenberg Laboratory, Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, 4th Floor, University Hospital MAS, S 205 02 Malmo, Sweden
    Genomics 84:147-56. 2004
    ..This is highly interesting with respect to animal models of benign prostate hyperplasia and prostate adenocarcinoma--diseases that have been described only in humans and dogs...
  61. ncbi Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
    Charlotte Becker
    Department of Clinical Chemistry, Lund University, University Hospital Malmo, Sweden
    J Urol 170:1169-74. 2003
    ..We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free (f) and total (t) prostate specific antigen (PSA) in a second round of biannual screening for prostate cancer...
  62. ncbi High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry
    David Finnskog
    Department of Electrical Measurement, Lund University, Lund, Sweden
    Electrophoresis 27:1093-103. 2006
    ..All biomarker digestions were completed in less than 30 s, with successful MS identification in the porous nanovial setting...
  63. ncbi Screening for prostate cancer: an update
    Shahrokh F Shariat
    Department of Surgery Urology Service, Clinical Laboratories, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Can J Urol 15:4363-74. 2008
    ....
  64. ncbi Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen
    David Ulmert
    Department of Surgery, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Discov 2:320-7. 2012
    ....
  65. ncbi Three genes expressing Kunitz domains in the epididymis are related to genes of WFDC-type protease inhibitors and semen coagulum proteins in spite of lacking similarity between their protein products
    Adam Clauss
    Lund University, Department of Laboratory Medicine, Clinical Chemistry, Skane University Hospital, SE 205 02 Malmo, Sweden
    BMC Biochem 12:55. 2011
    ..In this report, we have reinvestigated the locus for homologous genes encoding Kunitz motif only. The identified genes have been analyzed with respect to structure, expression and function...
  66. ncbi Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10021, USA
    J Clin Oncol 28:1112-6. 2010
    ..Clinicians who believe that it is unnecessary to prevent all cancers, but that preventing those readily detectable by screening would be desirable, would be best off recommending finasteride only to a high-risk subgroup...
  67. ncbi Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment
    Laila Bruun
    Department of Nephrology and Transplantation, University Hospital, Malmo, Sweden
    Nephrol Dial Transplant 18:598-603. 2003
    ..We evaluated whether established reference levels for %fPSA are applicable also to patients treated with haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)...
  68. ncbi Biology of prostate-specific antigen
    Hans Lilja
    Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, University Hospital UMAS, Malmo, Sweden
    Urology 62:27-33. 2003
    ....
  69. ncbi Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer
    George Botchorishvili
    Department of Clinical Laboratories, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Urol 19:221-6. 2009
    ..To delineate how recent findings on prostate-specific antigen (PSA) can improve prediction of risk, detection, and prediction of clinical endpoints of prostate cancer (PCa)...
  70. ncbi The evolution of a genetic locus encoding small serine proteinase inhibitors
    Adam Clauss
    Department of Laboratory Medicine, Clinical Chemistry, Lund University, University Hospital MAS, Malmo, Sweden
    Biochem Biophys Res Commun 333:383-9. 2005
    ..The conservation of different WFDC domains varies considerably, and it is hypothesized that this reflects a dual role of WFDC inhibitors in natural immunity, which is directed both against microbes and proinflammatory cells...
  71. ncbi A comprehensive nomenclature for serine proteases with homology to tissue kallikreins
    Ake Lundwall
    Lund University, Clinical Chemistry, Department of Laboratory Medicine, University Hospital MAS, S 205 02 Malmo, Sweden
    Biol Chem 387:637-41. 2006
    ..Here we present a new nomenclature in which proteins without proven kininogenase activity are denoted kallikrein-related peptidase. Names are also given to the unique rodent proteins that are closely related to kallikrein 1...
  72. ncbi Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation
    Anders Christensson
    Department of Nephrology and Transplantation, Malmo University Hospital, Malmo, Sweden
    Nephron Physiol 94:p19-27. 2003
    ....
  73. ncbi Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2
    Yue Cao
    Department of Urology, University Hospital Malmo, Lund University, SE 205 02 Malmo, Sweden
    Am J Pathol 161:2053-63. 2002
    ..Anti-thrombin may act as a local anti-angiogenic factor, the effect of which is partially lost in poorly differentiated prostatic tumors...
  74. ncbi Quantitative PSA RT-PCR for preoperative staging of prostate cancer
    Ralf Kurek
    Department of Urology, Academic Hospital Offenbach, Offenbach, Germany
    Prostate 56:263-9. 2003
    ..We used a quantitative RT-PCR assay to measure the PSA mRNA copy number in addition to the qualitative PSA RT-PCR and correlated the results with clinical parameters...
  75. ncbi The role of SPINK1 in ETS rearrangement-negative prostate cancers
    Scott A Tomlins
    Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Cancer Cell 13:519-28. 2008
    ..We identified the aggressive 22RV1 cell line as a SPINK1 outlier expression model and demonstrate that SPINK1 knockdown in 22RV1 attenuates invasion, suggesting a functional role in ETS rearrangement-negative prostate cancers...
  76. ncbi Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
    Alexander Haese
    Department of Urology, University Clinic Eppendorf, Hamburg, Germany
    J Urol 170:2269-73. 2003
    ....
  77. ncbi Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)
    Gunnar Aus
    Department of Urology, Sahlgrens University Hospital, Goteborg, Sweden
    Scand J Urol Nephrol 37:466-70. 2003
    ..To evaluate whether the free-to-total prostate-specific antigen (F/T-PSA) ratio can be used to differentiate between stage pT2 and pT3 prostate cancer...
  78. ncbi Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio
    Gunnar Aus
    Department of Urology, Sahlgrens University Hospital, S41345 Göteborg, Sweden
    Eur Urol 45:160-5. 2004
    ..To evaluate the cumulative risk of having a prostate cancer diagnosis in a repeated screening situation in relation to the free-to-total prostate specific antigen ratio (F/T-PSA)...
  79. ncbi Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening
    Björn Zackrisson
    Department of Urology, Sahlgrenska University Hospital, Goteborg, Sweden
    Eur Urol 43:327-32. 2003
    ..To study the follow-up of men with elevated prostate-specific antigen (PSA) (>3 ng/ml) after one benign set of sextant biopsies. From the Göteborg branch of the European Randomised Study of Screening for Prostate Cancer (ERSPC)...
  80. ncbi Standardization of two immunoassays for human glandular kallikrein 2
    Alexander Haese
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21287, USA
    Clin Chem 49:601-10. 2003
    ..We compared two hK2 assays and five different recombinant hK2 variants (rhK2) and suggest a common calibrator as an important step and putative reference substance in hK2 assay standardization...
  81. ncbi The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer
    Alexander Haese
    Department of Urology, University Hospital Hamburg, Germany
    Prostate 54:181-6. 2003
    ..In this study we investigated whether hK2 adds independent information when considered together with traditionally used parameters to predict organ confined (pT2a/b) PCa...
  82. ncbi Serum markers for prostate cancer: a rational approach to the literature
    Thomas Steuber
    Department of Urology, University Clinic Hamburg Eppendorf, Hamburg, Germany
    Eur Urol 54:31-40. 2008
    ..Therefore, novel biomarkers are much needed to complement PSA by enhancing its diagnostic and prognostic performance...
  83. ncbi Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen
    Thomas Steuber
    Department of Urology, University of Hamburg Eppendorf, Germany
    J Urol 168:1917-22. 2002
    ..To translate the encouraging statistical advantage shown in this study into a clinically applicable tool warrants further investigation...
  84. ncbi Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease
    Alice Ylikoski
    Department of Biotechnology, University of Turku, Finland
    Clin Chem 48:1265-71. 2002
    ..Further studies are needed to determine the diagnostic accuracy and prognostic value of the assays...
  85. ncbi Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
    Jonas Hugosson
    Department of Urology, Sahlgrenska Universitetssjukhuset, , Sweden
    J Urol 169:1720-3. 2003
    ..Men with a PSA of 2 to 3 ng./ml. or a value of greater than 3 ng./ml. with negative biopsy may be better served by a shorter screening interval. Thus, different screening intervals are implied depending on baseline PSA...
  86. ncbi The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable
    Bjørn Zackrisson
    Departments of Urology and Pathology, Sahlgrenska University Hospital, Goteborg, Sweden
    J Urol 171:1500-3. 2004
    ..We evaluated the significance of focal prostate cancer found in sextant biopsies in men participating in a biennial prostate specific antigen (PSA) based screening program...
  87. ncbi Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma
    Jonas Hugosson
    Department of Urology, Sahlrenska University Hospital, Gothenburg, Sweden
    Cancer 100:1397-405. 2004
    ..The purpose of the current study was to evaluate the effectiveness of a prostate carcinoma screening program in which serum prostate-specific antigen (PSA) levels were measured...
  88. ncbi Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer
    Alexander Haese
    Department of Urology, University Clinic Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Curr Urol Rep 5:231-40. 2004
    ..Newly discovered isoforms of free PSA also may impact early detection of prostate cancer with encouraging preliminary results that warrant further clinical investigation...
  89. ncbi Circulating biomarkers for prostate cancer
    Thomas Steuber
    Department of Urology, University Clinic Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    World J Urol 25:111-9. 2007
    ..This article will briefly discuss current PSA-based strategies and review several novel biomarkers for prostate cancer, detectable in blood...
  90. ncbi Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer
    Hans Lilja
    Clin Chem 54:1248-9. 2008
  91. ncbi Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer
    Hans Lilja
    J Clin Oncol 25:347-8. 2007
  92. ncbi Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments
    Ville Vaisanen
    Department of Biotechnology, University of Turku, Turku, Finland
    Anal Chem 78:7809-15. 2006
    ..F(ab')2 fragmentation was the most important factor in reducing interference. The optimized intact free PSA, free hK2, and total hK2 assays manifested high accuracy close to the lower limit of detection...
  93. ncbi Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial
    Gunnar Aus
    Department of Urology, Sahlgrens University Hospital, Goteborg, Sweden
    Eur Urol 51:659-64. 2007
    ..The aim of the present report is to evaluate whether PSA-based screening reduces the risk of being diagnosed with metastatic prostate cancer...
  94. ncbi Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study
    Gunnar Aus
    Department of Urology, Sahlgrens University Hospital, Goteborg, Sweden
    Arch Intern Med 165:1857-61. 2005
    ....
  95. ncbi beta-Microseminoprotein binds CRISP-3 in human seminal plasma
    Lene Udby
    Granulocyte Research Laboratory, Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Denmark
    Biochem Biophys Res Commun 333:555-61. 2005
    ..Structural similarity with an MSP-binding protein from blood plasma suggests that CRISP-3 binds MSP through its aminoterminal SCP-domain...
  96. ncbi Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade
    Alexander Haese
    Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 173:752-6. 2005
    ..Now we evaluated the usefulness of hK2, as measured by 2 entirely different immunoassay designs, to enhance the discrimination of pathologically organ from nonorgan confined clinical stage T1c PCa...
  97. ncbi Prediction of tumor heterogeneity in localized prostate cancer
    Hartwig Huland
    Department of Urology, University Clinics Hamburg Eppendorf, Martinistrasse 52, D 20246, Hamburg, Germany
    Urol Clin North Am 29:213-22. 2002
    ..Clinical T1 or T2 prostatic carcinoma is a heterogeneous but fairly predictable tumor...
  98. ncbi Development of sensitive immunoassays for free and total human glandular kallikrein 2
    Ville Vaisanen
    University of Turku, Department of Biotechnology, Finland
    Clin Chem 50:1607-17. 2004
    ..Concentrations of hK2 are 100-fold lower than concentrations of prostate-specific antigen (PSA); therefore, an hK2 assay must have a low detection limit and good specificity...
  99. ncbi Lead time associated with screening for prostate cancer
    Magnus Törnblom
    Department of Urology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
    Int J Cancer 108:122-9. 2004
    ..The ED program described here was not associated with major overdetection...
  100. ncbi Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue
    Thomas Steuber
    Department of Urology, University of Hamburg Eppendorf, Hamburg, Germany
    Prostate 63:13-8. 2005
    ....
  101. ncbi Integrated selective enrichment target--a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases
    Simon Ekström
    Department of Electrical Measurements, Lund Institute of Technology, Lund, Sweden
    Electrophoresis 25:3769-77. 2004
    ..The application of ISET sample preparation enabled multiple analyses to be performed on a limited sample volume, which resulted in the discovery that prolactin inducible protein (PIP) was coisolated from the samples...